



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office  
✉ production.office@frontiersin.org

RECEIVED 05 September 2023  
ACCEPTED 05 September 2023  
PUBLISHED 19 September 2023

## CITATION

Frontiers Production Office (2023) Erratum:  
Efficacy and safety of single-dose ivermectin in  
mild-to-moderate COVID-19: the  
double-blind, randomized, placebo-controlled  
CORVETTE-01 trial. *Front. Med.* 10:1289307.  
doi: 10.3389/fmed.2023.1289307

## COPYRIGHT

© 2023 Frontiers Production Office. This is an  
open-access article distributed under the terms  
of the [Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted which  
does not comply with these terms.

# Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

double-blind, ivermectin, SARS-CoV-2 proliferation, RT-PCR test, Japan

## An Erratum on

[Efficacy and safety of single-dose ivermectin in mild-to-moderate  
COVID-19: the double-blind, randomized, placebo-controlled  
CORVETTE-01 trial](#)

by Wada, T., Hibino, M., Aono, H., Kyoda, S., Iwadate, Y., Shishido, E., Ikeda, K., Kinoshita, N.,  
Matsuda, Y., Otani, S., Kameda, R., Matoba, K., Nonaka, M., Maeda, M., Kumagai, Y., Ako, J., Shichiri,  
M., Naoki, K., Katagiri, M., Takaso, M., Iwamura, M., Katayama, K., Miyatsuka, T., Orihashi, Y., and  
Yamaoka, K. (2023). *Front. Med.* 10:1139046. doi: 10.3389/fmed.2023.1139046

Due to a production error, an incorrect Conflict of Interest statement was provided. The correct Conflict of Interest statement appears below. The publisher apologizes for this mistake.

“The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

A reviewer of this manuscript, Devan Mehrotra, is a biostatistician at Merck & Co., Inc., known as MSD outside the United States and Canada. The pharmaceutical ivermectin studied in this manuscript is manufactured and marketed by Merck & Co., Inc. in the United States under the brand name STROMEKTOL<sup>®</sup>. After investigation, the journal has no reason to believe that the scientific conclusions of the article are affected in any way.”

The original article has been updated.